OXM
Fiscal year ends January Quarters are offset from the calendar — Q1 is Feb–Apr

Oxford Industries, Inc. is a branded apparel company that designs, sources, markets, and distributes products under a portfolio of lifestyle brands. The company operates through direct-to-consumer channels, including full-price retail stores, e-commerce websites, outlet stores, and food and beverage locations, as well as wholesale distribution to department stores and specialty retailers. Its brand portfolio includes Tommy Bahama, Lilly Pulitzer, Johnny Was, Southern Tide, TBBC, Duck Head, Jack Rogers, and The Beaufort Bonnet Company. The company serves the U.S. market, with a focus on warm-weather resort and travel-to destinations for its retail locations. Founded in 1865 as a manufacturer of private label apparel, the company transitioned to a brand stewardship model following the acquisition of Tommy Bahama. It maintains centralized support for its brands while allowing them creative autonomy.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Apparel Manufacturing Homepage oxfordinc.com
Sector Consumer Cyclical IR page investor.oxfordinc.com
Tags
lifestyle brands, resort wear, menswear, womenswear, childrenswear, direct-to-consumer, e-commerce, wholesale distribution, food and beverage, outlet retail, Tommy Bahama, Lilly Pulitzer, Johnny Was, Southern Tide, TBBC, Duck Head, Jack Rogers, The Beaufort Bonnet Company, Marlin Bars
Press page —

Metrics

Valuation  
Market cap $ 366.069M
Market cap (USD) $ 366.069M
P/E -56.84
PEG —
P/BV 0.65
P/S 0.25
P/OCF 2.66
P/FCF 7.02
Dividend yield 11.4%
Turnover / mcap —
Returns  
ROE -4.9%
ROI -4.4%
ROIC -3.7%
Profit margin -1.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 13.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.478B 1.517B 1.571B 1.412B 1.142B 748.833M 1.123B 1.107B 1.086B 1.023B 969.29M 997.806M 917.097M 855.542M 758.913M 603.947M — 1.129B 1.109B 1.314B 1.117B 764.602M 677.264M 812.495M 839.533M
Net profit -27.889M 92.973M 60.703M 165.735M 131.321M -95.692M 68.493M 66.291M 65.09M 52.461M 30.562M 45.758M 45.291M 31.317M 29.38M 78.658M — 52.137M 70.471M 49.827M 39.716M 20.327M 10.572M 15.346M 23.441M
Free cash flow 11.307M 59.801M 170.186M 78.942M 166.112M 54.926M 84.505M 59.334M 79.845M 69.15M 32.291M 45.054M 9.362M 6.75M 9.335M 22.363M — 28.294M 56.002M 28.093M 48.759M 25.542M 10.859M 70.061M 28.691M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 34.2 86.92 99.01 106.04 100.73 65.51 75.42 71.04 80.25 60.13 63.82 55.21 80.67 46.36 45.61 25.59 7 44.77 — — — — — — —
Price performance 12m -0.61 -0.12 -0.07 0.05 0.54 -0.13 0.06 -0.11 0.33 -0.06 0.16 -0.32 0.74 0.02 0.78 0.24 -0.71 — — — — — — — —

Filed figures

Figure Jan 2017 Jan 2018 Jan 2019 Jan 2020 Jan 2021 Jan 2022 Jan 2023 Jan 2024 Jan 2025 Jan 2026
Balance sheet detail
Trade receivables (USD) 58.3M 67.5M 69M 58.7M 30.4M 34.6M 44M 63.4M 72.4M 73M
↳ YoY growth -1.3% +15.9% +2.2% -14.9% -48.2% +13.6% +27.3% +44.1% +14.3% +0.7%
↳ 5y CAGR -0.5% +1.5% -1.7% -5.8% -12.4% -9.9% -8.2% -1.7% +4.3% +19.1%
Borrowings, non-current (USD) 91.5M 45.8M 13M — — — 119M 29.3M 31.1M 116M
Lease liabilities (USD) — — — 342M 301M 261M 295M 308M 418M 447M
Cash and deposits (USD) 6.33M 6.34M 8.33M 52.5M 66M 44.9M 8.83M 7.6M 9.47M 8.13M
Intangible assets (USD) 175M 179M 176M 175M 156M 155M 284M 262M 258M 189M
Right-of-use assets (USD) — — — 287M 234M 195M 241M 264M 364M 380M
Net debt (borrowings + leases - cash) (USD) 85.2M 39.5M 4.67M — — — 405M 330M 440M 555M
Cash flow detail
Operating cash flow (USD) 119M 119M 96.4M 122M 83.9M 198M 126M 244M 194M 120M
Purchases of property, plant and equipment (USD) -49.4M -38.7M -37M -37.4M -28.9M -31.9M -46.7M -74.1M -134M -108M
Change in receivables (cash effect) (USD) 7.38M -8.27M -1.56M 10.3M 28.4M -2.67M -1.97M -15M -7.65M 10.8M
Change in inventories (cash effect) (USD) 4.22M 19.5M -36.5M 8.19M 29.4M 5.38M -79M 62.5M -8.24M 3.19M
Change in payables (cash effect) (USD) — 1.29M 5.08M -14.3M 17.6M 27.6M 8.64M -28.1M 9.52M 15.4M
Dividends paid (cash effect) (USD) -18.1M -18.2M -23.1M -25.2M -16.8M -27.5M -35.3M -41.7M -43.2M -42.1M
Share buybacks (cash effect) (USD) -1.87M -2.21M -2.35M — -18.1M -8.36M -91.7M -20M 0.00 -55.2M
Interest paid (cash effect) (USD) -2.63M -2.77M -2.11M — — — — — — —
Income taxes paid (cash effect) (USD) -29.9M -20.7M -13.6M -17M -6M -34M -56M -39M — -11.1M
Share-based compensation (USD) 6.45M 6.41M 7.33M 7.62M 7.76M 8.19M 10.6M 14.5M 16.7M 15.7M
Operating cash flow before change in receivables (USD) 111M 127M 97.9M 112M 55.4M 201M 128M 259M 202M 109M
Free cash flow (OCF - PPE - intangibles) (USD) 69.2M 79.8M 59.3M 84.5M 54.9M 166M 78.9M 170M 59.8M 11.3M
Income detail
Total comprehensive income (USD) 54M 66.3M 65.3M 68.9M -94.7M 132M 167M 59.8M 92M -25.9M
Comprehensive income to owners (USD) 54M 66.3M 65.3M 68.9M -94.7M 132M 167M 59.8M 92M -25.9M
Provision for credit losses (USD) — — — 2M 4M -1M -1M — 1M 5M
Credit cost ratio (credit losses / average receivables) (%) — — — 3.1% 9.0% 3.1% 2.5% — 1.5% 6.9%
Reported Mar 28, 2017 Mar 30, 2020 Mar 30, 2020 Jun 10, 2021 Mar 28, 2022 Mar 28, 2022 Mar 31, 2025 Apr 1, 2024 Mar 27, 2026 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 29, 2026, Oxford Industries, Inc. (the “Company”) entered into a third amendment (the “Third Amendment”) to its $325 million Fourth Amended and Restated Credit Agreement, dated May 24, 2016 (the “Credit Agreement”), by and among the Company and its subsidiary, Tommy Bahama Group, Inc., as the borrowers, certain domestic subsidiaries of the Company as guarantors, the financial institutions party thereto as lenders, and Truist Bank, successor by merger to SunTrust Bank, as administrative agent. The Third Amendment, among other things, amends, and extends the term of, the Credit Agreement as follows:

•extends the maturity date of the facility from March 6, 2028 to October 29, 2031;
•streamlines the interest rate calculation by removing the SOFR credit spread adjustment with effective interest rates remaining unchanged;
•modifies certain provisions to allow additional flexibility in the payment conditions for acquisitions, investments and restricted payments;
•amends certain borrowing base provisions in the agreement; and
•makes certain other customary modifications to restrictions applicable to the Company and its subsidiaries.

ATLANTA, September 3, 2026 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its second quarter of fiscal 2026 ended August 1, 2026.

Consolidated net sales in the second quarter of fiscal 2026 were $394 million compared to $403 million in the second quarter of fiscal 2025. EPS on a GAAP basis was $3.25 compared to $1.12 in the second quarter of fiscal 2025, with the current year period reflecting a $2.07 tariff related refund impact recognized during the quarter. On an adjusted basis, EPS was $1.34 compared to $1.26 in the second quarter of fiscal 2025.

Tom Chubb, Chairman and CEO, commented, “Our second quarter results were in-line with our expectations, highlighted by year-over-year adjusted earnings per share growth and a low-single-digit comparable sales gain at Tommy Bahama. This performance contributed to strong cash flow generation in the first half of the year, which along with tariff refunds received to-date, we used to significantly reduce debt.”

Mr.

Shanghai, China – September 29, 2026 – Everest Medicines has been certified as a Top Employer in China for 2026 by the Top Employers Institute, a global authority on excellence in people practices. The certification recognizes the Company’s efforts to strengthen its talent development framework and enhance the employee experience, reinforcing its long-term commitment to building a strong organization and fostering talent development.

In 2026, the Institute certified nearly 2,500 organizations across 131 countries and regions. The certification evaluates companies’ people practices across six core areas: People Strategy, Work Environment, Talent Acquisition, Learning and Development, Diversity, Equity & Inclusion (DEI), and Wellbeing.

Organization and talent are among the core foundations supporting Everest Medicines’ progress toward its 2030 strategic goals. Through its “Growth Accelerator” talent strategy, the Company is building a high-quality talent base with strong functional expertise, strategic perspective and leadership capabilities, while strengthening its talent pipeline and organizational capabilities. Guided by an entrepreneurial culture characterized by “Hands-on, Results-driven, Self-motivated and Pragmatic-Efficiency,” Everest Medicines fosters a shared sense of purpose and values, supporting the growth of both its people and the organization.

Under its 2030 Strategy, Everest Medicines is focused on leveraging its highly efficient commercialization platform to deliver near-term, predictable value, while advancing a dual-engine model of “BD collaboration and in-house R&D” to generate long-term growth. The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion.

The Top Employer China 2026 certification demonstrates that Everest Medicines’ talent management practices have met rigorous international standards. It further underscores the Company’s continued commitment to building a strong organization and developing talent, while reinforcing its focus on advancing its organizational and talent capabilities.

Looking ahead, Everest Medicines is committed to becoming a global leading integrated biopharmaceutical company with sustainable growth, with the mission of “Better Medicines, Better Life”.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Back

Prompts

Oxford Industries, Inc. (ticker OXM), listed in United States.

ETFs Holding Oxford Industries, Inc.

ETF Weight in ETF Shares Market value As of
RUSC 0.13% 3,041 $ 106.04K Jun 30, 2026
BSVO 0.07% 61,447 $ 1.63M Nov 18, 2026
AVUV 0.06% 754,579 $ 20.434M Nov 16, 2026
IVSS 0.05% 367 $ 12.797K Jun 30, 2026
VFMF 0.04% 11,173 $ 427.814K Aug 31, 2026
AVSC 0.03% 30,828 $ 834.822K Nov 16, 2026
DFSV 0.02% 222,879 $ 6.31M Nov 12, 2026
DDDD 0.01% 24 $ 649.92 Nov 17, 2026
SFGV 0.01% 5,527 $ 150K Nov 18, 2026
DFAS 0.01% 96,412 $ 2.729M Nov 12, 2026
DFAT 0.01% 80,193 $ 2.27M Nov 12, 2026
DXUV 0.00% 9,260 $ 262.151K Nov 12, 2026
DFSU 0.00% 1,200 $ 33.972K Nov 12, 2026
DFAC 0.00% 30,802 $ 872.005K Nov 12, 2026
DCOR 0.00% 14,632 $ 414.232K Nov 12, 2026
DFAU 0.00% 3,455 $ 97.811K Nov 12, 2026
DFUS 0.00% 4,005 $ 113.382K Nov 12, 2026
EBI 0.00% 12 $ 459.48 Aug 31, 2026
AVUS 0.00% 10,091 $ 273.264K Nov 16, 2026
AVSU 0.00% 850 $ 23.018K Nov 16, 2026